BSE filing, NSE: PERMAGN. Summary written from the filing by ALFA Finder's alert engine.
Permanent Magnets Ltd: key numbers
- Share price
- ₹1,080.70
- Market cap
- ₹929.2 Cr
- Revenue (annual)
- ₹226.2 Cr
- Net profit (annual)
- ₹14.77 Cr
- P/E (TTM)
- 53.0×Sector 50.0×
- Promoter holding
- 58.07%+0.06% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Permanent Magnets Ltd
All →Permanent Magnets Investor Presentation: Key Takeaways
Q2 FY27 standalone revenue INR72.5 Cr (+49% YoY); EBITDA INR17.8 Cr (+159%), margin 25% on EV mix and operating leverage.
Permanent Magnets Results Update
Permanent Magnets Ltd released a press release on unaudited standalone and consolidated results for Q2FY27, reporting revenue of ₹72.46 Cr, up 49% YoY. Net profit rose 156% YoY to ₹9.98 Cr.
Permanent Magnets Q2 FY27 Results: Net Profit ₹7.5 Cr, Up 212.5% YoY
Permanent Magnets Ltd reported revenue from operations of ₹72.5 Cr (+47.7% YoY) and net profit of ₹7.5 Cr (+212.5% YoY) for Q2 FY27.
- Key figure
- Net profit ₹7.5 Cr · +212.5% YoY
Permanent Magnets Board Meeting Date
Permanent Magnets Limited has scheduled a board meeting for October 24, 2026. The board will consider and approve unaudited financial results for the quarter ended September 30, 2026.
Permanent Magnets Other Announcement
Permanent Magnets Ltd filed its quarterly shareholding pattern for the period ending September 30, 2026, noting a minor increase in promoter group holdings.
Permanent Magnets Management Change
Permanent Magnets Limited appointed Mr. Ayush Kumar Jain as Chief Financial Officer, effective October 1, 2026. He succeeds Mr. Sukhmal Jain, whose resignation is effective September 30.
Other regulatory approval announcements
All →Arihant Capital Markets Regulatory Approval
Arihant Capital Markets received SEBI in-principle approval to sponsor and set up a mutual fund. Final registration remains subject to SEBI's conditions.
Dr. Reddy's Laboratories Regulatory Approval
Dr. Reddy's Laboratories received marketing authorization from Brazil's ANVISA for its generic semaglutide injection. The approval targets Brazil's diabetes market, estimated at approximately USD 244.6 million.
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for its generic Olopatadine Hydrochloride Ophthalmic Solution 0.7% ANDA. The product's US market is estimated at $20 million, per IQVIA.
Emmbi Industries Regulatory Approval
SEBI exempted the Makrand and Rinku Appalwar business trusts from SAST takeover rules for an internal family share transfer. Control and promoter shareholding remain unchanged.
Bliss GVS Pharma Regulatory Approval
Bliss GVS Pharma's UK subsidiary Asterisk Lifesciences received MHRA marketing authorisation for Mesalazine 1g Suppositories. The approval lets the subsidiary market the product in the UK.
John Cockerill India Regulatory Approval
John Cockerill India received Reserve Bank of India approval for acquiring shares of John Cockerill Metals International SA. This allows the company to proceed with the share-swap acquisition.